摘要
目的评估安理申治疗轻、中度阿尔茨海默病(Alzheimer's disease,AD)和轻度认知功能障碍(mildcognitive impairment,MCI)的疗效。方法采用配对双盲法进行。42例AD和32例MCI患者入组,其中37例用安理申片5mg,每晚1次;另37例用吡拉西坦片800mg,3次/d,疗程均为12周。结果安理申组总有效率70%,吡拉西坦组为40%,差异有统计学意义(P<0.01)。安理申组AD患者简易智能状态量表(MMSE)及日常生活功能水平量表(FAQ)分数较治疗前明显改善(P<0.05、P<0.01);安理申不良反应轻。结论安理申治疗AD和MCI安全有效。
Objective To evaluate the therapeutic effects of donepzil on Alzheimer's disease and mild cognitive impairment. Methods Thirty-seven patients with Alzheimer' s disease and mild cognitive impairment in treatment group were treated with donepzil(5 rag) ,one time per day for 12 weeks; other 37 patients were treated with piracetam (800mg) , three times per day. Results The total effective rate of donepzil group(70% ) was signficantly higher than that of piracetam group(40% )(P 〈0. 01 ). The scales of Mini-mental State and daily life function of patients with Alzheimer's disease were improved after donepzil treatment. Adverse reactions of donepzil was mild. Conclusions Donepzil has a safe and therapeutic effect on Alzheimer's disease.
出处
《实用老年医学》
CAS
2007年第3期187-188,共2页
Practical Geriatrics